Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era

Overview of attention for article published in Current Oncology Reports, November 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 8 X users

Citations

dimensions_citation: 44 Dimensions

Readers on

mendeley: 79 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 15 X posts from 8 X users, with an upper bound of 19,848 followers.

@PTarantinoMD Absolutely not!!! Sorry but this is no EBM and would lead to hypes and potential arm to patients. There are scant data on ICI and Poor PS. Not to say that this approval is tvery criticisable https://t.co/HIJNDQ277G and https://t.co/pyI5puiNF0

18 Jun 2020

Reply Repost Favourite

RT @Alfdoc2: @RyanNipp @edubru @CancerCareMASCC Couldn’t agree more. We need better tool to properly assess fitness and even more now in th…

13 Jan 2020

Reply Repost Favourite

@RyanNipp @edubru @CancerCareMASCC Couldn’t agree more. We need better tool to properly assess fitness and even more now in the era of immunotherapy @gbanna74 @DralexGva https://t.co/mZHrnNQPuo

07 Jan 2020

Reply Repost Favourite

RT @Alfdoc2: Hot off press. ⁦@DralexGva⁩ ⁦@gbanna74⁩ Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remain…

28 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 11 additional X posts.